Advertisement
U.S. markets closed

Pulmatrix, Inc. (PULM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.9150-0.0450 (-2.30%)
At close: 03:22PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close1.9600
Open2.0000
Bid1.7400 x 2900
Ask1.9600 x 900
Day's Range1.9150 - 2.0000
52 Week Range1.6400 - 3.5000
Volume5,977
Avg. Volume18,291
Market Cap6.994M
Beta (5Y Monthly)0.89
PE Ratio (TTM)N/A
EPS (TTM)-4.4400
Earnings DateMar 28, 2024 - Apr 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PULM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Pulmatrix, Inc.
    Analyst Report: Viatris Inc.Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more